Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 919,231
  • Shares Outstanding, K 638,355
  • Annual Sales, $ 183,880 K
  • Annual Income, $ -85,780 K
  • EBIT $ -43 M
  • EBITDA $ -185 M
  • 60-Month Beta 0.58
  • Price/Sales 5.38
  • Price/Cash Flow N/A
  • Price/Book 3.98

Options Overview Details

View History
  • Implied Volatility 95.88% (-3.26%)
  • Historical Volatility 83.33%
  • IV Percentile 20%
  • IV Rank 8.41%
  • IV High 429.98% on 10/10/25
  • IV Low 65.22% on 06/04/25
  • Expected Move (DTE 15) 0.2125 (14.46%)
  • Put/Call Vol Ratio 1.67
  • Today's Volume 2,138
  • Volume Avg (30-Day) 2,423
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 69,875
  • Open Int (30-Day) 68,250
  • Expected Range 1.2575 to 1.6825

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.03
  • Number of Estimates 5
  • High Estimate -0.02
  • Low Estimate -0.03
  • Prior Year -0.03
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +5.00%
on 03/04/26
2.0100 -26.87%
on 02/19/26
unch (unch)
since 02/04/26
3-Month
1.2100 +21.49%
on 12/10/25
2.0100 -26.87%
on 02/19/26
+0.2000 (+15.75%)
since 12/04/25
52-Week
1.0400 +41.35%
on 11/07/25
2.0100 -26.87%
on 02/19/26
-0.1900 (-11.45%)
since 03/04/25

Most Recent Stories

More News
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.3800 (-4.50%)
NAGE : 4.94 (+1.44%)
GERN : 1.4700 (+2.08%)
NTLA : 13.82 (+1.58%)
OCGN : 1.9600 (+5.38%)
Geron: Q4 Earnings Snapshot

Geron: Q4 Earnings Snapshot

GERN : 1.4700 (+2.08%)
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025,...

GERN : 1.4700 (+2.08%)
Geron Plans to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.4700 (+2.08%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stock...

GERN : 1.4700 (+2.08%)
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.4700 (+2.08%)
Geron Corporation Provides 2026 Financial Guidance

2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line...

GERN : 1.4700 (+2.08%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock...

GERN : 1.4700 (+2.08%)
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Restructuring Supports RYTELO ® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE...

GERN : 1.4700 (+2.08%)
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin...

GERN : 1.4700 (+2.08%)

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.6300
2nd Resistance Point 1.5700
1st Resistance Point 1.5200
Last Price 1.4700
1st Support Level 1.4100
2nd Support Level 1.3500
3rd Support Level 1.3000

See More

52-Week High 2.0100
Fibonacci 61.8% 1.6395
Fibonacci 50% 1.5250
Last Price 1.4700
Fibonacci 38.2% 1.4105
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar